subject: Pipeline Insight: Non-insulin Antidiabetics - Rise Of The Weight-reducers: Once-weekly Glp-1 Agonist [print this page] Introduction Introduction
forecasts the non-insulins antidiabetics market to grow to $18.8 billion in 2019 for the seven major markets, with pipeline products contributing 39% of sales. GLP-1 agonists are driving pipeline growth, and the first launch of the novel SGLT-2 inhibitor class is also forecast.
Scope
*Comprehensive analysis of the current non-insulin antidiabetic pipeline detailing the broad range of developmental classes.
*A detailed clinical and commercial assessment of all key emerging therapies.
*Sales based sales forecasts for key late-stage developmental non-insulin antidiabetics agents in the seven major markets to 2019.
*Analysis of unmet needs in non-insulin diabetes therapies and key development R&D strategies in light of regulatory changes.
Highlights
A huge number of molecules are in development as non-insulin antidiabetics to meet the increase in patient population and disease unmet needs. 179 candidates are in clinical trials, and 16 Big Pharma companies are engaged in diabetes drug development.
GLP-1 agonists are likely to be the most successful pipeline candidates, and the class pipeline is forecast to generate sales of $3.7 billion in the seven major markets in 2019. Once-weekly Bydureon is forecast to be the class leader, despite FDA requirements for a new trial.
DPP-4 inhibitors will continue to grow driven by new combinations of marketed molecules. The launch of SGLT-2 inhibitors will provide another option in a crowded treatment algorithm for type 2 diabetes.
Reasons to Purchase
*Quantify the sales of pipeline drugs in the non-insulin antidiabetic market.
*Identify licensing opportunities based on company portfolio and market needs.
*Assess the remaining market opportunities and barriers to uptake for novel antidiabetic therapies.
Table of Contents :
Overview 1
Catalyst 1
Summary 1
About Our Healthcare Division 2
About the Cardiovascular and diabetes pharmaceutical analysis team 2
